Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem
Executive Summary
As Congress prepares to again debate patent reforms, brand industry says allegations of ‘patent thickets’ and extended market exclusivity are based on inaccurate or misleading data. They assert there is no need for PTO and FDA to institute systemic policy changes.